Navigation Links
Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University
Date:7/22/2010

WAYNE, N.J., July 22 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals is pleased to announce it will support the New Jersey Governor's School in the Sciences (NJGSS) at Drew University this summer.  This is the second year in a row that Bayer HealthCare Pharmaceuticals has sponsored the program, which is the longest running of the active Governor's schools.  

(Photo: http://photos.prnewswire.com/prnh/20100722/NY39266 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100722/NY39266 )

The NJGSS offers courses in neuroscience, cell biology, physics, mathematics, anthropology and chemistry. Eighty-five of the state's top math and science students representing 18 of New Jersey's 21 counties will participate in the three week program, which runs from July 11-31.  

"We challenge these outstanding high school juniors with an academic program that they usually would not experience until well into their college careers," said Dr. David Miyamoto, director of the NJGSS at Drew University.  "Students work together in teams on highly experiential research projects that lead to the writing of scientific-s
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... New Jersey (PRWEB) , ... September 01, 2015 , ... ... one of the 50 Best Companies for Latinas in the LATINA Style 50 Report ... United States. , For 2015, Horizon BCBSNJ climbs from number 24 ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and prevent different malignancies. Some options for cancer treatment are available belonging ... which distinctive approach is necessary for effective treatment. Several molecules have been ...
(Date:9/1/2015)... ... September 01, 2015 , ... As part of its ongoing ... of Minnesota (Blue Cross) has announced Doctor On Demand as the company’s preferred ... On Demand provides immediate access to Board Certified physicians or next-day appointments with ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure ... inside a wound to remove exudates, fluid, and infectious materials to prepare the ... stand-alone devices, disposable devices, and canisters, etc.) is projected to expand continuously through ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... Oct. 5 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... announced underwritten public offering. The Company sold 4,600,000,shares ... in its public offering,resulting in approximately $65.5 million ...
... Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) ... grant to Los Angeles Biomedical Research Institute at Harbor-UCLA ... penile endogenous (adult) stem cells with the company,s drug, ... the drug to provide long-term correction of male erectile ...
... monitoring over whole-brain radiotherapy , MONDAY, Oct. 5 ... learning and memory problems when whole-brain radiation therapy ... researchers have found. , SRS delivers narrowly focused ... The study included 58 patients with one to ...
... warns World Vision , - World Vision to open 13 ... calls on Indonesian government to prioritize its relief efforts to ... schoolchildren in Indonesia,s West Sumatra quake zone were called back ... of children affected by last week,s earthquake remain the disaster,s ...
... ... company, is launching its second "Boost Your Juice Contest" in October, in which healthcare ... win a free Internet marketing campaign worth up to $5,000. , ... Phoenix, AZ (PRWEB) October 5, 2009 ...
... Extent of the Prematurity Crisis Still Unknown, March of Dimes Says ... one million infants die each year because they are born too ... and Regional Toll of Preterm Birth. , The new White ... were born preterm -- defined as birth at less than 37 ...
Cached Medicine News:Health News:China-Biotics, Inc. Announces Closing of Public Offering of Common Stock 2Health News:China-Biotics, Inc. Announces Closing of Public Offering of Common Stock 3Health News:ESAI provides grant to LA BioMed to investigate long-term correction of erectile dysfunction 2Health News:Focused Radiation Protects Tumor Patients' Brain Function 2Health News:As Schools Reopen in Indonesia, World Vision Says Children's Basic Needs Still Not Being Met 2Health News:Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services 2Health News:Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services 3Health News:Global Death Toll: One Million Premature Babies Every Year 2Health News:Global Death Toll: One Million Premature Babies Every Year 3Health News:Global Death Toll: One Million Premature Babies Every Year 4Health News:Global Death Toll: One Million Premature Babies Every Year 5
... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
Medicine Products: